我要投票 博奥生物在基因检测行业中的票数:559
· 外 推 电 报 ·
2026-01-09 01:28:49 星期五

【博奥生物是哪个国家的品牌?】

博奥生物是什么牌子?「博奥生物」是 博奥生物集团有限公司 旗下著名品牌。该品牌发源于北京市,由创始人程总在2000年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力博奥生物品牌出海!将品牌入驻外推网,定制博奥生物品牌推广信息,可以显著提高博奥生物产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

成立于2000年,清华控股旗下,生命科学研究和健康产业的企业,打造集健康产品/健康管理和医疗康复于一体的大健康产业版块。

博奥生物集团有限公司于2000年9月30日在国务院、发改委、科技部、教育部、卫生部和北京市领导大力支持下,以清华大学为依托、联合华中科技大学、中国医学科学院、军事医学科学院注册成立,是生命科学研究和健康产业的国有创新型高科技企业。公司总部位于北京,现有员工2000多人,研发、生产、运营和服务基地超过10万平方米。

公司以生物芯片为核心技术平台,拥有研发、生产、销售以及全国第三方独立医学检验所服务为一体的大医学完整产业链,并响应国家关于“预防为主”的健康方针,将现代医学与中国传统医学紧密结合,打造出集健康产品、健康管理和医疗康复于一体的大健康产业版块。迄今,博奥生物在国内已经形成了北京、上海、重庆、成都等大型产业化基地,并形成了以北京博奥晶典生物技术有限公司为核心的产业化平台。

成立18年来,博奥生物依托清华大学和生物芯片北京国家工程研究中心雄厚的研发实力,已成功开发出生物芯片及相关试剂耗材、仪器设备、软件数据库、生命科学服务、临床检验服务、健康管理等系列数十项具有自主知识产权的产品和服务。公司先后获得德国TÜV莱茵公司颁发的ISO9001、ISO13485、ISO14000、ISO18000、ISO27000质量管理体系认证证书、美国组织相容性及遗传学协会(ASHI)认证证书和中国合格评定国家认可委员会实验室认证证书,其产品获得CFDA、CE 、GS、CB等国内外各类认证证书100余项。至今,博奥生物已在全球获得专利授权300余项,专利转化率较高。

因其优良的研发、生产、营销和服务团队,以及生物芯片技术平台和高标准的质保体系,博奥生物除与国内近百家三甲医院、高校、公安和司法机构建立了战略合作,还与罗氏应用科学、罗氏诊断、昂飞、热电等国际生命科学和医学诊断领域的公司建立了伙伴关系,产品及服务出口北美、欧洲、亚洲等三十多个国家和地区。其中,诊断用生物芯片及相关仪器产品已进入英国、德国、瑞典、意大利、西班牙、奥地利、瑞士、葡萄牙、芬兰、丹麦、日本、新加坡等国家的数百家医院。

英文翻译:Founded in 2000, Tsinghua holdings, a life science research and health industry enterprise, has created a large health industry section integrating health products / health management and medical rehabilitation. On September 30, 2000, with the support of the State Council, the national development and Reform Commission, the Ministry of science and technology, the Ministry of education, the Ministry of health and the leaders of Beijing Municipality, Bo'ao biological Group Co., Ltd. was established on the basis of Tsinghua University and registered with Huazhong University of science and technology, the Chinese Academy of Medical Sciences and the Academy of Military Medical Sciences. It is a state-owned innovative high-tech enterprise in life science research and health industry. The company is headquartered in Beijing, with more than 2000 employees and over 100000 square meters of R & D, production, operation and service bases. With biochip as the core technology platform, the company has a complete industrial chain of large-scale medicine integrating R & D, production, sales and the services of the national third-party independent medical laboratory. In response to the national health policy of "prevention first", the company closely combines modern medicine with traditional Chinese medicine to create a large-scale health industry integrating health products, health management and medical rehabilitation Industry forum. So far, Boao biology has formed large-scale industrialization bases in China, such as Beijing, Shanghai, Chongqing, Chengdu, and formed an industrialization platform with Beijing Boao Jingdian Biotechnology Co., Ltd. as the core. Since its establishment 18 years ago, relying on the strong R & D strength of Tsinghua University and biochip Beijing National Engineering Research Center, BOCOG bio has successfully developed dozens of products and services with independent intellectual property rights, including biochip and related reagent consumables, instruments and equipment, software database, life science services, clinical testing services, health management, etc. The company has successively obtained ISO9001, ISO13485, ISO14000, ISO18000, ISO27000 quality management system certification issued by Germany t Ü V Rhine company, Ashi certification and laboratory certification issued by China National Accreditation for conformity assessment. Its products have obtained more than 100 kinds of certification certificates at home and abroad, such as CFDA, CE, GS, CB, etc. So far, Bo'ao biology has obtained more than 300 patent authorizations in the world, with a high patent conversion rate. Due to its excellent R & D, production, marketing and service team, as well as the biochip technology platform and high standard quality assurance system, Boao biology has established strategic cooperation with nearly 100 top three hospitals, universities, public security and judicial institutions in China, as well as partnerships with companies in international life science and medical diagnosis fields such as Roche Applied Science, Roche diagnosis, onfe, thermoelectricity, etc Products and services are exported to more than 30 countries and regions in North America, Europe and Asia. Among them, diagnostic biochip and related instrument products have entered hundreds of hospitals in Britain, Germany, Sweden, Italy, Spain, Austria, Switzerland, Portugal, Finland, Denmark, Japan, Singapore and other countries.

本文链接: https://www.waitui.com/brand/126365a18.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

宏润建设:股东周美珍计划减持不超0.12%股份

36氪获悉,宏润建设公告,股东周美珍因个人资金需求,计划自公告披露之日起十五个交易日后的三个月内,即2026年1月30日至2026年4月29日,通过集中竞价交易方式减持公司股份不超过150.10万股,占剔除公司回购专用账户股份后总股本的0.12%。减持股份来源:因离婚财产分割、通过非交易过户取得的股份。

2小时前

欧盟反垄断监管机构定于2月10日前就谷歌收购Wiz的交易作出裁决

据欧盟委员会网站公示文件,欧盟反垄断监管机构将于2月10日前裁定,是否批准Alphabet以320亿美元收购网络安全公司Wiz的交易,这也是Alphabet有史以来规模最大的一笔收购。(新浪财经)

2小时前

谱尼测试:股票交易严重异常波动 预计2025年度亏损2亿元-2.5亿元

36氪获悉,谱尼测试公告,公司股票自2025年12月24日至2026年1月8日连续10个交易日内日收盘价格涨幅偏离值累计达到+100%,属于股票交易严重异常波动的情况。公司预计2025年度亏损2亿元到2.5亿元。经核实,公司不存在违反信息公平披露的情形,也无应披露而未披露的重大事项或处于筹划阶段的重大事项。公司提醒广大投资者理性投资,注意投资风险。

2小时前

美股大型科技股盘前涨跌不一,苹果跌超1%

36氪获悉,美股大型科技股盘前涨跌不一,截至发稿,苹果跌超1%,特斯拉跌0.88%,微软跌0.64%,Meta跌0.43%,奈飞跌0.32%;谷歌涨0.91%,英伟达涨0.31%,亚马逊涨0.23%。

2小时前

热门中概股美股盘前多数下跌,哔哩哔哩涨近3%

36氪获悉,热门中概股美股盘前多数下跌,截至发稿,拼多多、百度、爱奇艺跌超1%,京东跌0.72%,阿里巴巴跌0.48%,理想汽车跌0.35%,哔哩哔哩涨近3%,小鹏汽车涨超1%,蔚来涨0.21%。

2小时前

本页详细列出关于博奥生物的品牌信息,含品牌所属公司介绍,博奥生物所处行业的品牌地位及优势。
咨询